- 相似结构搜索
- InChIKey: FAPWYRCQGJNNSJ-UBKPKTQASA-L
- InChI=1S/2C9H17NO5.Ca/c2*1-9(2,5-11)7(14)8(15)10-4-3-6(12)13;/h2*7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13);/q;;+2/p-2/t2*7-;/m00./s1…
- 计算化学: 氢键受体数5.0氢键供体数4.0可旋转键数6.0
物理性质
- 熔点190 °C
- 沸点190 °C
- 闪点145 °C
- 密度3>1.266 g/ cm3
- PSA:191.72
- LogP:-0.849 (est)
- 旋光度26.5º(C=5,INWATER)
- 折射率27 ° (C=5, H2O)
- 溶解性H2O: 50 mg/mL at 25 °C, 澄清, 近乎无色
- 敏感性Hygroscopic
- 外观形态white crystalline powder
- 储存条件2-8 °C
- 产品应用本品为维生素类药物,是辅酶A的组成部分.在混旋泛酸钙中,只有右旋体具有维生素活性,参与蛋白质;脂肪;糖在体内的新陈代谢.用于维生素B缺乏症及周围神经炎,以及手术后的肠绞痛.与维生素C合用可治疗播散性红斑狼疮.人体缺乏泛酸钙具有如下症状:(1)生长停止,体重减少,突然死亡.(2)皮肤;毛发障碍.(3)神经系统障碍.(4)消化器官失常,肝功能障碍.(5)影响抗体形成.(6)副肾障碍.每天人体需要泛酸钙(以泛酸计)约5mg.泛酸钙作为营养增补剂,用于食品加工.除特殊营养食品外,使用量须在1(以钙计)以下(日本
- 性质描述白色针状结晶或粉末.熔点195-196°C(分解).每克本品溶于2.8毫升水,水溶液pH7.2-8.0;溶于甘油,微溶于乙醇和丙酮.稍有甜味,但转而微苦,具有中等吸湿性,对空气和光稳定.水解的程度取决于pH值,pH在5-7之间的水溶液最稳定,热压消毒时水溶液不稳定,因此,必须采用过滤灭菌的方法消毒.
上下游产品
sodium β-alaninate (R)-Pantolacton calcium-N-(2,4-dihydroxy-3,3-dimethylbutyryl)-β-alaninate calcium beta-alaninateD-pantethine 3-amino propanoic acid 2,2-dimethyl-3-hydroxypropionaldehyde carbon dioxide 海关参考信息
- 2905122000-异丙醇
2905399001-1,3-丙二醇
2912110000-甲醛
2912120000-乙醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-11046978-B2
优先权日:2016-03-16
标 题:Synthesis of isoprenoids and derivatives
发明人:GONZALEZ RAMON; CLOMBURG JAMES M; CHEONG SEOKJUNG
权利人:UNIV RICE WILLIAM M
摘要:This disclosure generally relates to the use of enzyme combinations or recombinant microbes comprising same to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds. Novel metabolic pathways exploiting Claisen, aldol, and acyioin condensations are used instead of the natural mevalonate (MVA) pathway or 1-deoxy-d-xylulose 5-phosphate (DXP) pathways for generating isoprenoid precursors such as isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), and geranyl pyrophosphate (GPP). These pathways have the potential for better carbon and or energy efficiency than native pathways. Both decarboxylative and non-carboxylative condensations are utilized, enabling product synthesis from a number of different starting compounds. These condensation reactions serve as a platform for the synthesis of isoprenoid precursors when utilized in combination with a variety of metabolic pathways and enzymes for carbon rearrangement and the addition/removal of functional groups. Isoprenoid alcohols are key intermediary products for the production of isoprenoid precursors in these novel synthetic metabolic pathways.
专利号:US-2023091651-A1
优先权日:2021-09-20
标 题:Dietary supplement and method for synthesis of same
发明人:WYNN JASON R
权利人:StrongCell LLC
摘要:A dietary supplement and method for synthesis of the same are disclosed. In one embodiment of the method, an NADH component is provided that includes at least partially microencapsulated nicotinamide having nicotinamide blended with water. A supplement component, such as collagen, coenzyme Q10, vitamins, and minerals, is provided. A mixed component, which is a liquid, is formed by mixing the NADH component with the supplement component at ambient conditions. The mixed component is subjected to a fill production process.
专利号:US-2023089537-A1
优先权日:2021-09-20
标题:Dietary supplement and method for synthesis of same
发明人:WYNN JASON R
权利人:StrongCell LLC
摘要:A dietary supplement and method for synthesis of the same are disclosed. In one embodiment of the method, an NADH component is provided which includes NADH from about 0.1% to about 0.5% blended with water from about 40% to about 84% both by weight of the dietary supplement. A supplement component from about 9% to about 99% by weight of the dietary supplement is also provided. The supplement component may include collagen in about 2% to about 10%, vitamins in about 0.00001% to about 3%, and minerals in about 0.000002% to about 0.5% all by weight of the dietary supplement. A mixed component is formed by mixing the NADH component with the supplement component at ambient conditions. The mixed component is a liquid at ambient conditions having a pH of less than 4.0. The mixed component is subjected to a cold fill production process.
专利号:WO-2019228873-A1
优先权日:2018-05-31
标 题:Synthesis of a racemic mixture of pantolactone
发明人:BONRATH WERNER; BOURGEOIS FREDERIC; MEDLOCK JONATHAN; SPARR CHRISTOF
权利人:DSM IP ASSETS BV
摘要:The invention relates to an improved synthesis of a racemic mixture of pantolactone (I).
专利号:WO-2019228874-A1
优先权日:2018-05-31
标 题 :Stereoselective synthesis of enantiomerically-enriched pantolactone
发明人:BONRATH WERNER; BOURGEOIS FREDERIC; MEDLOCK JONATHAN; SPARR CHRISTOF
权利人:DSM IP ASSETS BV
摘要:The present invention relates stereoselective synthesis of enantiomerically enriched pantolactone.
专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as